法国生物技术公司Aqemia利用人工智能技术在药物发现和设计领域取得了突破性进展，近日宣布获得6000万欧元的A轮融资。其中，3000万欧元为追加融资，由Wendel Growth领投，现有投资者法国风险投资公司Eurazeo、公共银行Bpifrance和Elaia参投。
Aqemia公司开发的人工智能驱动技术，能够加速分子的发现和设计，这些分子有望成为对抗各种疾病的药物。据悉，该技术在药物研发领域具有广泛的应用前景，将为新药的研发和上市提供更高效、更经济的解决方案。
作为一家初创公司，Aqemia的成功融资表明了资本市场对其人工智能驱动技术的认可和期待。此轮融资将用于进一步推进公司在药物发现和设计领域的研发工作，加快新药的上市进程，为全球患者带来更多希望。
英文标题：AI-Driven Aqemia Secures €60 Million in Funding
英文关键词：AI-driven, biotechnology, financing
英文新闻内容：
French biotech company Aqemia, which utilizes artificial intelligence technology in drug discovery and design, has recently announced a €60 million Series A round of financing. Of this amount, €30 million is an additional financing led by Wendel Growth, with existing investors including French venture capital firm Eurazeo, public bank Bpifrance, and Elaia participating.
Aqemia has developed an AI-driven technology that accelerates the discovery and design of molecules, which could potentially become drugs to combat various diseases. Reportedly, this technology has broad application prospects in the field of drug development and offers a more efficient and cost-effective solution for new drug research, development, and market authorization.
As a startup, Aqemia’s successful financing demonstrates the capital market’s recognition and expectations for its AI-driven technology. The proceeds from this round of financing will be used to further advance the company’s research and development efforts in drug discovery and design, accelerate the launch of new drugs, and bring more hope to patients worldwide.
【来源】https://sifted.eu/articles/aqemia-60m-series-a
Views: 1